Top Page
BioVaxys Technology
(BIOV)
BioVaxys Technology (BIOV) vs. iShares MSCI Canada ETF (EWC)
BioVaxys Technology Business Overview & Revenue Model
BioVaxys Technology Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -3.99M | -3.95M | -7.69M | 0.00 | -6.42M | -1.09M |
| Net Income | -6.04M | -3.95M | -7.69M | -11.73M | -6.46M | -1.17M |
Balance Sheet | ||||||
| Total Assets | 1.39M | 1.30M | 113.48K | 865.56K | 8.50M | 10.46M |
| Cash, Cash Equivalents and Short-Term Investments | 4.08K | 211.81K | 977.00 | 141.90K | 593.12K | 2.42M |
| Total Debt | 133.72K | 68.08K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.03M | 3.22M | 3.49M | 1.64M | 326.86K | 900.09K |
| Stockholders Equity | -3.64M | -1.92M | -3.37M | -773.53K | 8.18M | 9.56M |
Cash Flow | ||||||
| Free Cash Flow | -2.97M | -2.92M | -1.05M | -1.57M | -5.29M | -1.23M |
| Operating Cash Flow | -2.97M | -1.86M | -1.05M | -1.57M | -5.29M | -1.23M |
| Investing Cash Flow | 0.00 | -1.06M | 0.00 | 0.00 | 0.00 | 61.36K |
| Financing Cash Flow | 2.48M | 3.13M | 917.10K | 1.11M | 3.44M | 3.35M |
BioVaxys Technology Technical Analysis
BioVaxys Technology Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | C$39.40M | -10.17 | ― | ― | ― | 72.92% | |
44 Neutral | C$64.60M | -5.54 | -91.21% | ― | ― | 54.74% | |
43 Neutral | C$18.90M | -0.15 | -409.25% | ― | ― | 62.01% | |
43 Neutral | C$356.14K | -5.10 | -10.82% | ― | ― | 46.32% | |
29 Underperform | C$7.29M | -1.12 | ― | ― | ― | 25.09% | |
26 Underperform | C$83.96M | -34.60 | ― | ― | ― | 10.49% |
BioVaxys Technology Corporate Events
BioVaxys’ 2025 corporate review highlights the integration of the DPX platform into its operations and a strategic shift toward organic growth by expanding its early-stage pipeline, pursuing out-licensing opportunities, and re-engaging clinical investigators for Phase 1 trials of DPX-based formulations. The company strengthened its scientific and business development capabilities with the appointment of veteran vaccine executive Dr. James Tartaglia to the board and DPX expert Dr. Marianne Stanford as scientific advisor, moves that have facilitated outreach to major vaccine and pharmaceutical companies for potential collaborations in infectious diseases and oncology. Operationally, BioVaxys is focusing on out-licensing its lead candidate maveropepimut-S (MVP-S) in selected indications to limit internal funding demands, while its recent positive Phase 1 results in HR+/HER2- stage II–III breast cancer position the company to potentially tap into the sizeable and growing global HER2-negative breast cancer market, enhancing its profile in the competitive immuno-oncology and vaccine landscape.
BioVaxys Technology Corp. has reported positive phase 1 clinical study results for its innovative candidate MVP-S in combination with letrozole for treating HR+/HER2- stage II-III breast cancer. The trial demonstrated strong immune responses and significant decreases in tumor proliferation markers among patients, highlighting potential progress in addressing unmet therapeutic needs in this subgroup. The breakthrough strengthens BioVaxys’ position as an innovator in targeted cancer immunotherapy and could mark advancements in personalized treatment alternatives in the larger oncology market.
BioVaxys Technology Corp. has appointed Dr. Marianne Stanford as a Scientific Advisor, strengthening its scientific team with her extensive experience in vaccine development. Dr. Stanford’s expertise with the DPX platform, particularly in oncology and infectious diseases, is expected to enhance BioVaxys’s capabilities in developing DPX as a delivery platform for mRNA and other polypeptides, potentially impacting the company’s operations and market positioning.
BioVaxys Technology Corp. has completed a debt settlement transaction by issuing 1,792,387 common shares to settle an outstanding debt of $412,249. This move is part of the company’s financial strategy to manage its liabilities and strengthen its financial position. The transaction reflects BioVaxys’s ongoing efforts to optimize its capital structure, which may impact its operational capabilities and market positioning. The securities issued are subject to a four-month statutory hold period, indicating compliance with applicable securities legislation.
BioVaxys Technology Corp. has successfully closed a non-brokered private placement financing, raising approximately $1.92 million through the issuance of over 11 million units. The funds will be utilized to enhance the company’s pipeline growth by pursuing licensing opportunities, conducting research collaborations, and expanding its DPX formulations for immunotherapies. Additionally, the proceeds will support the development of a peanut allergy vaccine program and the filing of new patents, positioning BioVaxys as a key player in targeted immunotherapies.
BioVaxys Technology Corp. has announced a debt settlement transaction with certain creditors, agreeing to issue up to 1,792,387 common shares at a deemed value of $0.23 per share to settle an outstanding debt of $412,249. This transaction, subject to regulatory approvals, aims to strengthen the company’s financial position and potentially enhance its market operations, reflecting a strategic move to manage its liabilities while continuing its focus on developing its clinical-stage pipeline.
BioVaxys Technology Corp. announced an extension of its non-brokered private placement financing to allow more investors to participate. The offering aims to raise up to $2,000,000 through the sale of units, each consisting of one common share and one purchase warrant. The proceeds will be used to expand the company’s pipeline through licensing opportunities, research collaborations, and the development of its DPX platform for various immunotherapy applications. This move is expected to enhance BioVaxys’s position as a key player in targeted immunotherapies, potentially benefiting stakeholders by broadening its market reach and increasing its research capabilities.
BioVaxys Technology Corp. has announced an increase in its non-brokered private placement financing, aiming to raise up to $2 million. The proceeds will be used to expand its pipeline through licensing opportunities, research collaborations, and preclinical studies, particularly focusing on its DPX platform for targeted immunotherapies. This move is expected to enhance BioVaxys’s position as a key partner in the immunotherapy sector and support its ongoing development of cancer and allergy treatments.
BioVaxys Technology Corp. announced the conversion of $125,000 in unsecured convertible debentures into common shares, resulting in the issuance of 665,465 shares at a conversion price of $0.19 per share. This conversion reflects investor confidence and provides the company with additional equity, potentially enhancing its financial flexibility and market position.
BioVaxys Technology Corp. has announced the conversion of $160,670 in debentures into common shares, resulting in the issuance of 954,179 shares at a conversion price of $0.17 per share. This conversion reflects a strategic financial maneuver to manage its outstanding debt, potentially enhancing its market position by increasing equity and reducing liabilities, subject to regulatory approvals.
BioVaxys Technology Corp. announced the conversion of $25,000 in unsecured convertible debentures into common shares by its CEO, James Passin, a transaction considered a related party transaction. Additionally, the company granted 550,000 stock options to its directors, officers, consultants, and employees, which are convertible into shares at an exercise price of $0.25, vesting over a year. These moves reflect BioVaxys’s ongoing efforts to strengthen its financial position and incentivize its leadership and staff, potentially impacting its market standing and stakeholder interests.
BioVaxys Technology Corp. and its licensee, SpayVac-for-Wildlife, Inc., have announced positive results from a study on their immunocontraceptive vaccine, SpayVac, which significantly reduced fertility in deer. The vaccine, which uses a patented liposome-based delivery platform, has shown efficacy in multiple deer species and is now undergoing regulatory submission for use in managing feral horses and deer populations. This development holds significant commercial potential due to the challenges of managing overabundant deer populations, which can cause ecological and agricultural damage. SpayVac offers a less invasive and potentially more cost-effective alternative to surgical sterilization and short-acting contraceptives, with ongoing trials in other species further expanding its potential market applications.
BioVaxys Technology Corp has appointed Dr. James Tartaglia, a former executive from Sanofi Vaccines, to its Board of Directors. Dr. Tartaglia’s extensive experience in vaccine R&D is expected to bolster BioVaxys’s strategic focus on DPX-based vaccine programs and collaborations with global vaccine companies, potentially enhancing its industry positioning and impact on stakeholders.
BioVaxys Technology Corp. has announced a non-brokered private placement financing to raise between $1.2 million and $1.6 million through the sale of units consisting of common shares and warrants. The proceeds will be used to expand the company’s pipeline by pursuing licensing opportunities, research collaborations, and initiating a food allergy program, among other activities. This financing is expected to enhance BioVaxys’s position as a partner for targeted immunotherapies and support its ongoing development efforts.